Abstract

The purpose of the studywas to determine the role of antibiotics as a risk factor of Clostridium difficile-associated diarrhea in hospitalized cancer patients.Material and Methods. The study included 844 hospitalized cancer patients with diarrhea. The presence of Clostridium difficile toxins A and B in the fecal samples was determined by enzyme immunoassay.Results.Clostridium difficile toxins A and B were detected in 100 cancer patients (42 % men and 58 % women). The incidence of Clostridium difficile-associated diarrhea was higher in women than in men (р<0.02). Patients with hemoblastosis and gastrointestinal tumors were more susceptible to the development of Clostridium difficile associated diarrhea (p<0.02). The use of cephalosporin antibiotics was the main risk factor (р<0.001). In our study, 46 % of the patients took antibiotics.Conclusion.Clostridium difficile was shown to play a significant role in the development of diarrhea in cancer patients, and early detection of Clostridium difficile infection contributes to the early onset of therapy.

Highlights

  • ОПЫТ РАБОТЫ ОНКОЛОГИЧЕСКИХ УЧРЕЖДЕНИЙ higher in women than in men (р≤0.02)

  • The purpose of the study was to determine the role of antibiotics as a risk factor of Clostridium difficileassociated diarrhea in hospitalized cancer patients

  • The presence of Clostridium difficile toxins A and B in the fecal samples was determined by enzyme immunoassay

Read more

Summary

Introduction

ОПЫТ РАБОТЫ ОНКОЛОГИЧЕСКИХ УЧРЕЖДЕНИЙ higher in women than in men (р≤0.02). Patients with hemoblastosis and gastrointestinal tumors were more susceptible to the development of Clostridium difficile associated diarrhea (p≤0.02). The purpose of the study was to determine the role of antibiotics as a risk factor of Clostridium difficileassociated diarrhea in hospitalized cancer patients. Clostridium difficile toxins A and B were detected in 100 cancer patients (42 % men and 58 % women).

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call